Denali Therapeutics (DNLI) Total Liabilities (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Total Liabilities data on file, last reported at $339.9 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 128.66% year-over-year to $339.9 million in Q1 2026; TTM through Mar 2026 was $339.9 million, a 128.66% increase from a year earlier, with the FY2025 full-year figure at $131.1 million, down 9.28% from the prior year.
• Total Liabilities for Q1 2026 stood at $339.9 million, up from $131.1 million in the prior quarter.
• Over the last five years, Total Liabilities for DNLI reached as high as $442.6 million in Q1 2023 and fell as low as $115.5 million in Q2 2024.
• Historically, Total Liabilities has averaged $226.9 million across 5 years, with a median of $139.2 million in 2025.
• Across the five-year window, Total Liabilities plunged 71.62% in 2024 and soared 128.66% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $417.8 million in 2022, then sank by 70.57% to $123.0 million in 2023, then climbed by 17.51% to $144.5 million in 2024, then declined by 9.28% to $131.1 million in 2025, then soared by 159.3% to $339.9 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $339.9 million in Q1 2026, $131.1 million in Q4 2025, and $129.4 million in Q3 2025.